Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer

被引:60
作者
Rasch, Morten G. [1 ]
Lund, Ida K. [1 ]
Almasi, Charlotte E. [1 ]
Hoyer-Hansen, Gunilla [1 ]
机构
[1] Rigshosp, Finsen Lab, Copenhagen Bioctr, Sect 3735, DK-2200 Copenhagen N, Denmark
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2008年 / 13卷
关键词
uPAR cleavage; uPA; monoclonal antibodies; TR-FIA; prognosis; diagnosis; cancer; plasminogen activation; review;
D O I
10.2741/3186
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cellular receptor for urokinase, uPAR, localizes its ligand, uPA, and thereby the plasminogen activation, to the cell surface. uPA also cleaves uPAR, liberating the ligand-binding domain I, and thereby inactivates the binding potential of uPAR for both uPA and vitronectin. The uPA-catalyzed cleavage of uPAR is fast on the cell surface, when uPA is bound to a neighboring uPAR molecule. uPAR can be shed from the cell surface. However, the soluble form cannot be cleaved by uPA. Glycolipid-anchored and soluble forms of intact, uPAR(I-III), and cleaved receptor, uPAR(II-III) and uPAR(I), have been identified in tissue and body fluids. It is well-established, that the total amount of all uPAR forms is a strong prognostic marker in different types of cancer. Using immunoassays, measuring the individual uPAR forms, has revealed that the cleaved uPAR forms are even stronger prognostic markers and have diagnostic utility. This review will focus on the mechanism of uPAR cleavage and the functional consequences, as well as the clinical applicability of cleaved uPAR forms.
引用
收藏
页码:6752 / 6762
页数:11
相关论文
共 94 条
  • [1] Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue
    Almasi, CE
    Hoyer-Hansen, G
    Christensen, IJ
    Dano, K
    Pappot, H
    [J]. LUNG CANCER, 2005, 48 (03) : 349 - 355
  • [2] Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice
    Almholt, K
    Lund, LR
    Rygaard, J
    Nielsen, BS
    Dano, K
    Romer, J
    Johnsen, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (04) : 525 - 532
  • [3] The plasminogen activation system in tumor growth, invasion, and metastasis
    Andreasen, PA
    Egelund, R
    Petersen, HH
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) : 25 - 40
  • [4] Structural basis of interaction between urokinase-type plasminogen activator and its receptor
    Barinka, Cyril
    Parry, Graham
    Callahan, Jennifer
    Shaw, David E.
    Kuo, Alice
    Bdeir, Khalil
    Cines, Douglas B.
    Mazar, Andrew
    Lubkowski, Jacek
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2006, 363 (02) : 482 - 495
  • [5] The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling
    Behrendt, N
    [J]. BIOLOGICAL CHEMISTRY, 2004, 385 (02) : 103 - 136
  • [6] BEHRENDT N, 1991, J BIOL CHEM, V266, P7842
  • [7] BEHRENDT N, 1990, J BIOL CHEM, V265, P6453
  • [8] Urokinase receptor cleavage: A crucial step in 14 fibroblast-to-myofibroblast differentiation
    Bernstein, Audrey M.
    Twining, Sally S.
    Warejcka, Debra J.
    Tall, Edward
    Masur, Sandra K.
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2007, 18 (07) : 2716 - 2727
  • [9] uPAR: A versatile signalling orchestrator
    Blasi, F
    Carmeliet, P
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (12) : 932 - 943
  • [10] Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression
    Bolon, I
    Zhou, HM
    Charron, Y
    Wohlwend, A
    Vassalli, JD
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (06) : 2299 - 2304